DailyMed Label: RYDAPT

DailyMed Label: RYDAPT

2024

DailyMed Prescription

RYDAPT

RYDAPT

Novartis Pharmaceuticals Corporation

NDC: 0078-0698

NDC: 0078-0698

Midostaurin is a kinase inhibitor for oral use. The molecular formula for midostaurin is C 35 H 30 N 4 O 4 . The molecular weight is 570.65 g/mol. The chemical name of midostaurin is Benzamide, N -[(9 S ,10 R ,11 R ,13 R )-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1 H ,9 H -diindolo[1,2,3- gh :3′,2′,1′- lm ]pyrrolo[3,4- j ][1,7]benzodiazonin-11- yl ]- N -methyl-. The chemical structure of midostaurin is shown below: RYDAPT is supplied as a soft capsule containing 25 mg of midostaurin. The capsule contains carmine, corn oil mono-di-triglycerides, dehydrated alcohol, ferric oxide red, ferric oxide yellow, gelatin, glycerin 85%, hypromellose 2910, polyethylene glycol 400, polyoxyl 40 hydrogenated castor oil, propylene glycol, purified water, titanium dioxide, and vitamin E. Structural Formula

RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 ) RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by an FDA approved test [see Dosage and Administration (2.1), Clinical Studies (14.1)]. Limitations of Use RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. RYDAPT is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

AML : 50 mg orally twice daily with food. ( 2.1 , 2.2 , 2.4 ) ASM, SM-AHN, and MCL : 100 mg orally twice daily with food. ( 2.3 , 2.4 ) Select patients for the treatment of AML with RYDAPT based on the presence of FLT3 mutation positivity [see Clinical Studies (14)] . Information on FDA-approved tests for the detection of FLT3 mutation in AML is available at: http://www.fda.gov/CompanionDiagnostics. The recommended dose of RYDAPT for patients with AML is 50 mg orally twice daily with food on Days 8 to 21 of each cycle of induction with cytarabine and daunorubicin and on Days 8 to 21 of each cycle of consolidation with high-dose cytarabine. For a description of the experience with single-agent treatment with RYDAPT beyond induction and consolidation [see Clinical Studies (14.1)] . The recommended dose of RYDAPT for patients with ASM, SM-AHN, and MCL is 100 mg orally twice daily with food. Continue treatment until disease progression or unacceptable toxicity occurs. Table 1 provides recommendations for dose modifications of RYDAPT in patients with ASM, SM-AHN, and MCL. Monitor patients for toxicity at least weekly for the first 4 weeks, every other week for the next 8 weeks, and monthly thereafter while on treatment. Table 1: RYDAPT Dose Modifications for Patients with Systemic Mastocytosis Criteria RYDAPT Dosing ANC less than 1 x 10 9 /L attributed to RYDAPT in patients without MCL, or ANC less than 0.5 x 10 9 /L attributed to RYDAPT in patients with baseline ANC value of 0.5-1.5 x 10 9 /L Interrupt RYDAPT until ANC greater than or equal to 1 x 10 9 /L, then resume RYDAPT at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily. Discontinue RYDAPT if low ANC persists for greater than 21 days and is suspected to be related to RYDAPT. Platelet count less than 50 x 10 9 /L attributed to RYDAPT in patients without MCL, or platelet count less than 25 x 10 9 /L attributed to RYDAPT in patients with baseline platelet count of 25-75 x 10 9 /L Interrupt RYDAPT until platelet count greater than or equal to 50 x 10 9 /L, then resume RYDAPT at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily. Discontinue if low platelet count persists for greater than 21 days and is suspected to be related to RYDAPT. Hemoglobin less than 8 g/dL attributed to RYDAPT in patients without MCL, or life-threatening anemia attributed to RYDAPT in patients with baseline hemoglobin value of 8 to 10 g/dL Interrupt RYDAPT until hemoglobin greater than or equal to 8 g/dL, then resume RYDAPT at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily. Discontinue if low hemoglobin persists for greater than 21 days and is suspected to be related to RYDAPT. Grade 3/4 nausea and/or vomiting despite optimal anti-emetic therapy Interrupt RYDAPT for 3 days (6 doses), then resume RYDAPT at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily. Other Grade 3/4 non-hematological toxicities Interrupt RYDAPT until event has resolved to less than or equal to Grade 2, then resume RYDAPT at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily. Abbreviations: ANC, absolute neutrophil count; MCL, mast cell leukemia. National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) severity: Grade 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms; 4 = life-threatening symptoms. Administer prophylactic anti-emetics before treatment with RYDAPT to reduce the risk of nausea and vomiting. Administer RYDAPT orally with food, twice daily at approximately 12-hour intervals [see Clinical Pharmacology (12.3)]. Do not open or crush RYDAPT capsules. If a dose of RYDAPT is missed or vomited, do not make up the dose; take the next dose at the usual scheduled time. Consider interval assessments of QT by electrocardiogram (ECG) if RYDAPT is taken concurrently with medications that can prolong the QT interval.

25 mg capsules: pale orange oblong soft capsule with red ink imprint ‘PKC NVR’. Capsules: 25 mg ( 3 )

RYDAPT is contraindicated in patients with hypersensitivity to midostaurin or to any of the excipients [see Description (11)]. Hypersensitivity reactions have included anaphylactic shock, dyspnea, flushing, chest pain, and angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) [see Adverse Reactions (6.1)]. Hypersensitivity to midostaurin or any of the excipients. ( 4 )

Embryo-Fetal Toxicity : RYDAPT may cause fetal harm when administered to a pregnant woman. Advise of the potential risk to a fetus. ( 5.1 , 8.1 ) Pulmonary Toxicity : Monitor for symptoms of interstitial lung disease or pneumonitis. Discontinue RYDAPT in patients with signs or symptoms of pulmonary toxicity. Fatal cases have occurred. ( 5.2 ) Based on its mechanism of action and findings from animal reproduction studies, RYDAPT may cause fetal harm when administered to pregnant women. In animal studies, midostaurin caused embryo-fetal toxicities, including late embryo-fetal death and reduced fetal birth weight, with delays in fetal growth at doses lower than the recommended human dose. Advise pregnant women of the potential risk to the fetus. Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating RYDAPT therapy. Advise females of reproductive potential to use effective contraception during treatment with RYDAPT and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with RYDAPT and for 4 months after the last dose [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1)] . Cases of interstitial lung disease and pneumonitis, some fatal, have occurred in patients treated with RYDAPT as monotherapy or with chemotherapy. Monitor patients for pulmonary symptoms. Discontinue RYDAPT in patients who experience signs or symptoms of interstitial lung disease or pneumonitis without an infectious etiology. Prolonged Grade 4 neutropenia and thrombocytopenia occurred in two pediatric patients with AML who received an unapproved formulation of midostaurin in combination with chemotherapy, including anthracyclines, fludarabine, and cytarabine; these two patients were coadministered an azole antifungal (a strong CYP3A4 inhibitor), which may increase midostaurin concentrations and subsequently, the risk of toxicity [see Drug Interactions (7.1), Use in Specific Populations (8.4)] . The safety and effectiveness of RYDAPT in pediatric patients have not been established.

The following serious adverse reactions are described elsewhere in the labeling:

Strong CYP3A4 Inhibitors : Strong CYP3A4 inhibitors may increase exposure to midostaurin and its active metabolites. Consider alternative therapies that do not strongly inhibit CYP3A4 or monitor for increased risk of adverse reactions. ( 7.1 ) Strong CYP3A4 Inducers : Avoid concomitant use as strong CYP3A4 inducers decrease exposure to midostaurin and its active metabolites. ( 7.1 ) CYP2B6, BCRP, OATP1B1 Substrates : Dose adjustments for coadministered CYP2B6, BCRP, and OATP1B1 substrates may be necessary with RYDAPT. ( 7.2 ) Table 6 lists the potential effects of the coadministration of strong CYP3A modulators on RYDAPT. Table 6: Drug Interactions with RYDAPT That Affect Midostaurin   Strong CYP3A Inhibitors a The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was used (e.g., low dose, single strength). b The induction potency of St. John’s wort may vary widely based on preparation.   Clinical Impact Coadministration of RYDAPT with strong CYP3A inhibitors may increase midostaurin concentrations. The increase in midostaurin concentrations may be pronounced if strong CYP3A inhibitors are administered during the first week of RYDAPT administration [see Clinical Pharmacology (12.3)]. Increased midostaurin concentrations may increase the risk of toxicity.   Prevention or Management Consider alternative therapies that do not strongly inhibit CYP3A activity. Alternatively, with coadministration of RYDAPT and strong CYP3A inhibitors, monitor patients for increased risk of adverse reactions, especially during the first week of consecutive RYDAPT administration in advanced SM population, and during first week of RYDAPT administration in each cycle of chemotherapy in AML population.   Examples Boceprevir, clarithromycin, cobicistat, conivaptan, danoprevir and ritonavir, diltiazem, elvitegravir and ritonavir, grapefruit juice a , idelalisib, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, nefazodone, nelfinavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, tipranavir and ritonavir, troleandomycin, voriconazole   Strong CYP3A Inducers   Clinical Impact Coadministration of RYDAPT with strong CYP3A inducers may decrease midostaurin concentrations [see Clinical Pharmacology (12.3)]. Decreased midostaurin concentrations may reduce efficacy.   Prevention or Management Avoid coadministration of RYDAPT with strong CYP3A4 inducers.   Examples Carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John’s wort b CYP2B6 Substrates RYDAPT decreased the systemic exposure of a sensitive CYP2B6 substrate [see Clinical Pharmacology (12.3)] . Dose adjustments for the coadministered CYP2B6 substrate may be necessary with RYDAPT. Substrates of Transporters Coadministration of RYDAPT increased the exposure of a breast cancer resistance protein (BCRP) and organic anion transporter polypeptide (OATP)1B1 substrate [see Clinical Pharmacology (12.3)] . Dose adjustments for the coadministered BCRP or OATP1B1 substrates may be necessary with RYDAPT.

Lactation : Advise females not to breastfeed. ( 8.2 ) Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to RYDAPT during pregnancy. Females who may have been exposed to RYDAPT during pregnancy directly or through a male partner receiving RYDAPT therapy should contact the Novartis Pharmaceuticals Corporation at 1-888-669-6682 and/or at https://report.novartis.com/ . Risk Summary Based on mechanism of action and findings in animal reproduction studies, RYDAPT may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available data on RYDAPT use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal reproduction studies, oral administration of midostaurin to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicities, including late embryo-fetal death and reduced fetal birth weight, with delays in fetal growth at doses lower than the recommended human dose (see Data) . Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population are unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data When midostaurin was administered to female rats prior to mating and through the first week of pregnancy at a dose of 60 mg/kg/day [approximately 0.1 times the human exposure at the recommended dose based on area under the curve (AUC)], there were increases in pre- and post-implantation loss, including total litter loss, resulting in a reduction in the number of live embryos. During organogenesis, midostaurin administered at oral doses greater than or equal to 3 mg/kg/day (approximately 0.004 times the human exposure at the recommended dose by AUC) to pregnant female rats caused late embryo-fetal death. Dilated lateral brain ventricles were observed in offspring of rats given doses greater than or equal to 3 mg/kg/day. Extra rib and reduced fetal birth weight with effects on fetal growth (severe renal pelvic cavitation and widened anterior fontanelle) were observed in the absence of maternal toxicity at the highest dose of 30 mg/kg/day (approximately 0.05 times the human exposure at the recommended dose by AUC). Midostaurin administered orally to pregnant rabbits during organogenesis led to maternal toxicity with spontaneous abortions and some delay in fetal growth (reduced fetal birth weight) at doses greater than or equal to 10 mg/kg/day (approximately 0.01 times the human exposure at the recommended dose by AUC). In an oral pre- and postnatal development study in the rat, adverse effects upon maternal performance included dams with signs of dystocia and a lower live litter size at 30 mg/kg/day (approximately 0.05 times the human exposure at the recommended dose by AUC). For the F1 offspring, lower body weights, accelerated complete eye opening and delayed auricular startle ontogeny were noted at 30 mg/kg/day. Risk Summary There are no data on the presence of midostaurin or its active metabolites in human milk, the effect on the breastfed infant, or the effect on milk production. Orally administered midostaurin and its active metabolites pass into the milk of lactating rats within 1 hour of a 30 mg/kg/day dose, with approximately 5 times more in the milk of lactating rats compared to plasma. Because of the potential for serious adverse reactions in breastfed infants from RYDAPT, advise women not to breastfeed during treatment with RYDAPT and for 4 months after the last dose. RYDAPT may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)] . Pregnancy Testing Pregnancy testing is recommended for females of reproductive potential within seven days prior to initiating RYDAPT. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with RYDAPT and for 4 months after the last dose. Males Advise males with female partners of reproductive potential to use effective contraception during RYDAPT treatment and for 4 months after stopping treatment with RYDAPT [see Nonclinical Toxicology (13.1)] . Infertility Based on findings in animals, RYDAPT may impair fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see Nonclinical Toxicology (13.1)] . Safety and effectiveness of RYDAPT have not been established in pediatric patients. The safety and effectiveness of an unapproved midostaurin formulation was investigated, but not established in two open-label studies: a study in 22 pediatric patients aged 6 months to 17 years who received midostaurin as a single agent for relapsed or refractory leukemia [NCT00866281] and a study in 4 patients aged 8 to 14 years who received midostaurin in combination with chemotherapy for newly diagnosed FLT3-mutated AML [NCT03591510]. Prolonged Grade 4 neutropenia and thrombocytopenia occurred in 2 of the 4 pediatric patients with AML who received midostaurin in combination with chemotherapy, including anthracyclines, fludarabine, and cytarabine [see Warnings and Precautions (5.3)] . Grade 4 thrombocytopenia lasted for 44 days in one patient and Grade 4 thrombocytopenia and Grade 4 neutropenia lasted for 51 days and 46 days, respectively, in the other patient. These two patients were coadministered an azole antifungal (a strong CYP3A4 inhibitor), which may increase midostaurin concentrations and subsequently, the risk of toxicity [see Drug Interactions (7.1)] . Of the 142 patients with advanced SM in clinical studies of RYDAPT, 64 (45%) were aged 65 and over, and 16 (11%) were aged 75 years and over. No overall differences in safety or response rate were observed between the subjects aged 65 and over compared with younger subjects. Greater sensitivity of older individuals cannot be ruled out. Clinical studies in AML with RYDAPT did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, administration for elderly patients should be cautious, based on patient’s eligibility for concomitant chemotherapy and reflecting the greater frequency of concomitant disease or other drug therapy.

RYDAPT 25 mg capsules Pale orange oblong soft capsule with red ink imprint ‘PKC NVR’; available in: 56 soft capsules………………………………………………………………………………………NDC 0078-0698-99 Contents: Each carton contains two inner packs, each with 28 capsules (7 blister cards with 4 capsules each) 112 soft capsules……………………………………………………………………………………..NDC 0078-0698-19 Contents: Each carton contains four inner packs, each with 28 capsules (7 blister cards with 4 capsules each) Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Store in the original container to protect from moisture.

Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type and D816V mutant), PDGFRα/β, as well as members of the serine/threonine kinase PKC (protein kinase C) family. Midostaurin demonstrated the ability to inhibit FLT3 receptor signaling and cell proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD mutant FLT3 receptors or overexpressing wild type FLT3 and PDGF receptors. Midostaurin also demonstrated the ability to inhibit KIT signaling, cell proliferation and histamine release and induce apoptosis in mast cells. Cardiac Electrophysiology The effect of RYDAPT (75 mg twice daily for 3 days) on the QTc interval was evaluated in a randomized, placebo and moxifloxacin controlled, multiple-dose, blinded, parallel study. There was no clinically significant prolongation of QTc interval or relationship between changes in QTc and concentrations for midostaurin and its active metabolites (CGP62221 and CGP52421). The study duration was not long enough to estimate the effects of the metabolite CGP52421 on the QT/QTc interval. In pooled clinical studies in patients with advanced SM, 4.7% patients had a post-baseline QTcF > 480 ms, no patients had a QTcF > 500 ms, and 6.3% patients had a QTcF > 60 ms compared to baseline. In a randomized placebo-controlled study in patients with AML, the proportion of patients with QTc prolongation was higher in patients randomized to midostaurin as compared to placebo (QTcF > 480 ms: 10.1% vs 5.7%; QTcF > 500 ms: 6.2% vs 2.6%; QTcF > 60 ms change from baseline: 18.4% vs 10.7%). Midostaurin exhibits time-dependent pharmacokinetics with an initial increase in minimum concentrations (C min ) that reach the highest C min concentrations during the first week followed by a decline to a steady-state after approximately 28 days. The pharmacokinetics of the CGP62221 showed a similar trend. The plasma concentrations of CGP52421 continued to increase after one month of treatment. The highest C min and steady-state of midostaurin, CGP62221, and CGP52421 were similar when RYDAPT was administered with food at a dose of 50 mg twice daily or 100 mg twice daily. Absorption The time to maximal concentrations (T max ) occurred between 1 to 3 hours post dose in the fasted state. Effect of Food Midostaurin exposure, represented by AUC over time to infinity (AUC inf ), increased 1.2-fold when RYDAPT was coadministered with a standard meal (457 calories, 50 g fat, 21 g proteins, and 18 g carbohydrates) and 1.6-fold when coadministered with a high-fat meal (1007 calories, 66 g fat, 32 g proteins, and 64 g carbohydrates) compared to when RYDAPT was administered in a fasted state. Midostaurin maximum concentrations (C max ) were reduced by 20% with a standard meal and by 27% with a high-fat meal compared to a fasted state. T max was delayed when RYDAPT was administered with a standard meal or a high-fat meal (median T max = 2.5 hrs to 3 hrs) [see Dosage and Administration (2.5)]. Distribution Midostaurin has an estimated geometric mean volume of distribution (% coefficient of variation) of 95.2 L (31%). Midostaurin and its metabolites are distributed mainly in plasma in vitro . Midostaurin, CGP62221, and CGP52421 are greater than 99.8% bound to plasma protein in vitro . Midostaurin is mainly bound to α1-acid glycoprotein in vitro . Elimination The geometric mean terminal half-life (% coefficient of variation) is 19 hours (39%) for midostaurin, 32 hours (31%) for CGP62221 and 482 hours (25%) for CGP52421. Metabolism Midostaurin is primarily metabolized by CYP3A4. CGP62221 and CGP52421 (mean ± standard deviation) account for 28 ± 2.7% and 38 ± 6.6% respectively of the total circulating radioactivity. Excretion Fecal excretion accounted for 95% of the recovered dose with 91% of the recovered dose excreted as metabolites and 4% of the recovered dose as unchanged midostaurin. Only 5% of the recovered dose was found in urine. Specific Populations Age (20 to 94 years), sex, race, mild (total bilirubin greater than 1.0 to 1.5 times the ULN or aspartate aminotransferase (AST) greater than the ULN) or moderate (total bilirubin 1.5 to 3.0 times the ULN and any value for AST) hepatic impairment, and renal impairment (creatinine clearance (CLCr) ≥ 30 mL/min) did not have clinically meaningful effects on the pharmacokinetics of midostaurin, CGP62221, or CGP52421. The pharmacokinetics of midostaurin in patients with baseline severe hepatic impairment (total bilirubin greater than 3.0 times the ULN and any value for AST) or severe renal impairment (CLCr 15 to 29 mL/min) is unknown. Drug Interaction Studies Clinical Studies and Model-Informed Approaches Effect of Strong CYP3A4 Inhibitors on Midostaurin Coadministration of ketoconazole (a strong CYP3A4 inhibitor) with a single dose of RYDAPT (50 mg) increased AUC inf of midostaurin by 10.4-fold and CGP62221 by 3.5-fold and area under the curve over time to last measurable concentrations (AUC 0-t ) of CGP52421 by 1.2-fold compared to a single RYDAPT dose coadministered with placebo [see Drug Interactions (7.1)]. Coadministration of itraconazole (a strong CYP3A4 inhibitor) with multiple doses of RYDAPT (100 mg twice daily on Days 1 to 2 and 50 mg twice daily on Days 3 to 28) increased Day 28 C min concentrations of midostaurin by 2.1-fold, CGP62221 by 1.2-fold, and CGP52421 by 1.3-fold compared to the respective Day 21 C min concentrations with RYDAPT alone [see Drug Interactions (7.1)]. Effect of Strong CYP3A4 Inducers on Midostaurin Coadministration of rifampicin (a strong CYP3A4 inducer) with a single dose of RYDAPT (50 mg) decreased AUC inf of midostaurin by 96% and CGP62221 by 92% and AUC 0-t of CGP52421 by 59% [see Drug Interactions (7.1)] . Effect of Midostaurin on CYP2B6 Substrates Coadministration of multiple doses of RYDAPT (50 mg twice daily) at steady-state with a single dose of bupropion (a sensitive CYP2B6 substrate) decreased the AUC inf of bupropion by 48% and hydroxybupropion by 65% [see Drug Interactions (7.2)] . Effect of Midostaurin on CYP3A, CYP2C8, CYP2D6 Substrates Coadministration of multiple doses of RYDAPT (50 mg twice daily) at steady-state with single doses of midazolam (a sensitive CYP3A substrate) or pioglitazone (a moderate sensitive CYP2C8 substrate) did not affect AUC inf of midazolam or pioglitazone. However, the effect of multiple doses of RYDAPT on sensitive substrates of CYP3A and CYP2C8 during the first week, when midostaurin trough concentrations are highest, is unknown. Coadministration of a single dose of RYDAPT (100 mg) with a single dose of dextromethorphan (a sensitive CYP2D6 substrate) did not affect the AUC inf of dextromethorphan. The effect of multiple doses of RYDAPT on dextromethorphan is unknown. Coadministration of multiple doses of RYDAPT (50 mg twice daily) at steady-state with a single dose of a hormonal contraceptive containing ethinyl estradiol and levonorgestrel (CYP3A4 substrates) increased the area under the curve over time to the last measurable concentration (AUC last ) of ethinyl estradiol by 10% and levonorgestrel by 42%. However, the effect of multiple doses of RYDAPT on ethinyl estradiol and levonorgestrel during the first week, when midostaurin trough concentrations are highest, is unknown. Effect of Midostaurin on P-gp, BCRP, and OATP1B1 Substrates Coadministration of a single dose of RYDAPT (100 mg) with a single dose of rosuvastatin (BCRP and OATP1B1 substrate) increased the AUC last of rosuvastatin by 48%. RYDAPT 50 mg twice daily at steady state is predicted to increase the AUC of an OATP1B1 substrate up to 2-fold, with unknown effect on a BCRP substrate [see Drug Interactions (7.2)] . Coadministration of a single dose of RYDAPT (100 mg) with a single dose of digoxin (sensitive P-gp substrate) did not affect the AUC inf of digoxin. The effect of multiple doses of RYDAPT on digoxin is unknown. In Vitro Studies Effect of Midostaurin on CYP Enzymes Midostaurin inhibits CYP1A2 and CYP2E1; CGP62221 inhibits CYP1A2 in vitro . Midostaurin, CGP52421, and CGP62221 induce CYP1A2 in vitro .

Carcinogenicity studies have not been performed with midostaurin. Midostaurin was not mutagenic in vitro in the bacterial reverse mutation assay (Ames test) or in Chinese hamster V97 cells. Midostaurin increased the frequency of polyploidy cells in an in vitro chromosomal aberrations assay in Chinese hamster ovary cells, but was not clastogenic in an in vivo rat bone marrow micronucleus assay when tested to the maximum tolerated dose (MTD) of 200 mg/kg (1,200 mg/m 2 ). This dose was approximately 20-fold the recommended human dose, based on body surface area. Reproductive toxicity was observed in a fertility study, in male and female rats given oral doses of midostaurin at 10, 30 and 60 mg/kg/day (approximately 0.01, 0.05, and 0.1 times, respectively, the AUC at the recommended human dose). In males, testicular degeneration and atrophy was observed at doses greater than or equal to 10 mg/kg/day and reduced sperm count and motility, and a decrease in reproductive organ weights were observed at 60 mg/kg/day. In females, increased resorptions, decreased pregnancy rate, and decreased number of implants and live embryos were observed at 60 mg/kg/day. In a 3-month toxicology study in dogs, there was inhibition of spermatogenesis at doses greater than or equal to 3 mg/kg/day (approximately 0.01 times the exposure at the recommended human dose).

Study 1 RYDAPT in combination with chemotherapy was investigated in a randomized, double-blind placebo-controlled trial of 717 patients with newly-diagnosed FLT3-mutated AML. In this study, FLT3 mutation status was determined prospectively with a clinical trial assay and verified retrospectively using the companion diagnostic LeukoStrat ® CDx FLT3 Mutation Assay, which is an FDA-approved test for selection of patients with AML for RYDAPT treatment. Patients were stratified by FLT3 mutation status: TKD, ITD with allelic ratio less than 0.7, and ITD with allelic ratio greater than or equal to 0.7. Patients with acute promyelocytic leukemia or therapy-related AML were not eligible. Patients were randomized (1:1) to receive RYDAPT 50 mg twice daily (n = 360) or placebo (n = 357) with food on Days 8 to 21 in combination with daunorubicin (60 mg/m 2 daily on Days 1 to 3) /cytarabine (200 mg/m 2 daily on Days 1 to 7) for up to two cycles of induction and high dose cytarabine (3 g/m 2 every 12 hours on Days 1, 3, and 5) for up to four cycles of consolidation, followed by continuous RYDAPT or placebo treatment according to initial assignment for up to 12 additional 28-day cycles. There was no re-randomization at the start of post consolidation therapy. Patients who proceeded to hematopoietic stem cell transplantation (SCT) stopped receiving study treatment. The randomized patients had a median age of 47 years (range, 18 to 60 years), 44% were male, and 88% had a performance status of 0-1. AML was de novo onset in 95%. The percentage of patients with FLT3-ITD allelic ratio < 0.7, FLT3-ITD allelic ratio ≥ 0.7, and FLT3-TKD mutations were identical (per randomized FLT3 stratum) on both arms (48%, 30%, and 23%, respectively). Of the 563 patients with NPM1 testing, 58% had an NPM1 mutation. The two treatment groups were generally balanced with respect to the baseline demographics and disease characteristics, except that the placebo arm had a higher percentage of females (59%) than in the midostaurin arm (52%). NPM1 mutations were identified in 55% of patients tested on the midostaurin arm and 60% of patients tested on the placebo arm. A second course of induction was administered to 25% of the patients, 62% initiated at least one cycle of consolidation, 29% initiated maintenance, and 17% completed all 12 planned cycles of maintenance; 21% of the patients underwent SCT in first CR. The overall rate of SCT (induction failure, first CR or salvage after relapse) was 59% (214/360) of patients in the RYDAPT plus standard chemotherapy arm versus 55% (197/357) in the placebo plus standard chemotherapy arm. All patients were followed for survival. Efficacy was established on the basis of overall survival (OS), measured from the date of randomization until death by any cause. The primary analysis was conducted after a minimum follow-up of approximately 3.5 years after the randomization of the last patient. RYDAPT plus standard chemotherapy was superior to placebo plus standard chemotherapy in OS [HR 0.77; 95% confidence interval (CI) 0.63, 0.95; 2-sided p = 0.016] (Figure 1). Because survival curves plateaued before reaching the median, median survival could not be reliably estimated. Figure 1: Kaplan-Meier Curve for Overall Survival in Study 1 The analysis of event-free survival (EFS), defined as a failure to obtain a complete remission (CR) within 60 days of initiation of protocol therapy, or relapse, or death from any cause, showed a statistically significant improvement with a median of 8.2 months for RYDAPT plus standard chemotherapy versus 3.0 months for placebo plus standard chemotherapy with HR 0.78 (95% CI 0.66, 0.93) and 2-sided p = 0.005. In an exploratory analysis of EFS defined as a failure to obtain a CR any time during induction, or relapse, or death from any cause with failures assigned as an event on study Day 1, the median EFS was 10.6 months for RYDAPT plus standard chemotherapy versus 5.6 months for placebo plus standard chemotherapy with HR 0.72 (95% CI 0.61, 0.86). Figure 1: Kaplan-Meier Curve for Overall Survival in Study 1 Study 2 A single-arm, open-label, multicenter trial evaluated the efficacy of RYDAPT as a single agent in ASM, SM-AHN, and MCL, collectively referred to as advanced SM. The study enrolled 116 adult patients with relapse or progression to 0, 1, or 2 prior regimens for SM. The study excluded patients with serum creatinine > 2.0 mg/dL, hepatic transaminases > 2.5 x ULN or > 5 x ULN if disease-related, total bilirubin > 1.5 x ULN or > 3 x ULN if disease-related, QTc > 450 msec, cardiovascular disease, including left-ventricular ejection fraction < 50%, or any pulmonary infiltrates. In addition, the study excluded patients with acute-stage or life-threatening AHN. Patients received RYDAPT 100 mg orally twice daily in 28-day cycles until disease progression or intolerable toxicity. Of the 116 patients treated, a study steering committee identified 89 patients who had measurable C-findings and were evaluable for response. The median age in this group was 64 years (range, 25 to 82), 64% of patients were male, and nearly all patients (97%) were Caucasian. Among these patients, 36% had prior therapy for SM, and 82% had the KIT D816V mutation detected at baseline. Their median duration of treatment was 11 months (range, < 1 to 68 months), with treatment ongoing in 17%. Efficacy was established on the basis of confirmed complete remission (CR) plus incomplete remission (ICR) by 6 cycles of RYDAPT by modified Valent criteria for ASM and SM-AHN (Table 7). Table 7 shows responses to RYDAPT according to modified Valent criteria. Confirmed major or partial responses occurred in 46 of 73 patients with a documented KIT D816V mutation, 7 of 16 with wild-type or unknown status with respect to KIT D816V mutation, and 21 of 32 having prior therapy for SM. Table 7: Efficacy of RYDAPT in Systemic Mastocytosis per Modified Valent Criteria (Study 2) Modified Valent Criteria All Patients Evaluated e (N = 89) ASM (N = 16) SM-AHN (N = 57) MCL (N = 16) CR + ICR by 6 cycles, n a,b       (95% CI, %) 19 (21%) (13, 31) 6 (38%) (15, 65) 9 (16%) (7, 28) 4 (25%) (7, 52) Median duration of CR + ICR (months) c       (95% CI)       Range d NR (24.1, NE) 6.6+, 65.8+ NR (24.1, NE) 12.1+, 36.8+ NR (7.4, NE) 6.6+, 52.1+ NR (NE, NE) 19.1+, 65.8+ Median time to CR + ICR (months)       Range 0.5 0.1, 3.0 0.7 0.3, 1.9 0.5 0.1, 3.0 0.3 0.1, 0.5 Abbreviations: ASM, aggressive systemic mastocytosis; CI, confidence interval; CR, complete remission; ICR, incomplete remission; MCL, mast cell leukemia; NE, not estimated; NR, not reached; SM-AHN, systemic mastocytosis with associated hematological neoplasm. a Per Study Steering Committee. Response confirmation after ≥ 8 weeks was required. No CRs were reported. b Patients who received concomitant high-dose corticosteroids were considered unevaluable and were excluded from response assessment. c Among patients with a response of CR or ICR. The estimated median follow-up for duration of response (DOR) was 35.4 months overall. d A " + " sign indicates a censored value. e 25 patients were not assessable for the presence of MCL on central histopathology review, and 11 patients with unconfirmed presence of AHN were regarded as not having AHN. As a post-hoc exploratory analysis, efficacy was also assessed using modified 2013 International Working Group-Myeloproliferative Neoplasms Research and Treatment-European Competence Network on Mastocytosis (IWG-MRT-ECNM) consensus criteria. Response after 6 cycles of RYDAPT was determined using a computational algorithm. The efficacy of RYDAPT for MCL was based on the CR results by these criteria. There were 115 patients evaluable for response assessment, of whom 47 (41%) had prior therapy for SM, and 93 (81%) had a documented D816V mutation at baseline. Table 8 provides the results of this analysis. Overall response by modified IWG-MRT-ECNM criteria was reported for 16 (17%) of 93 patients with a documented D816V mutation, and in 8 (17%) of 47 patients having prior therapy for SM. Table 8: Efficacy of RYDAPT in Systemic Mastocytosis per Modified IWG-MRT-ECNM Consensus Criteria Using an Algorithmic Approach (Study 2) All Patients Evaluated (N = 115) b, c ASM (N = 16) SM-AHN (N = 72) MCL (N = 21) Subtype not Established (N = 6) Overall response in 6 cycles, n a     (95% CI) 19 (17%) (10, 25) 5 (31%) (11, 59) 8 (11%) (5, 21) 4 (19%) (5, 42) 2 (33%) (4, 78) Best overall response, n     Complete remission     Partial remission 2 (2%) 17 (15%) 1 (6%) 4 (25%) 0 (0%) 8 (11%) 1 (5%) 3 (14%) 0 (0%) 2 (33%) Duration of response (months) d     Range e 6.8+, 60.5+ 10.2+, 36.4+ 6.8+, 51.8+ 8.6+, 55.9+ 27.3+, 60.5+ Abbreviations: ASM, aggressive systemic mastocytosis; IWG-MRT-ECNM, international working group-myeloproliferative neoplasms research and treatment-european competence network on mastocytosis; MCL, mast cell leukemia; SM-AHN, systemic mastocytosis with associated hematological neoplasm. a Determined with 12-week confirmation. Patients who received high-dose corticosteroids were considered evaluable for response. b Median exposure to midostaurin was 11.5 (range, 0.3, 68.3) months. c 31 patients were not assessable for MCL on central review, and 15 patients with unconfirmed AHN were classified as not having AHN. d Median duration of response (DOR) was not reached in any subtype. Median follow up for DOR, among all responders, was 35.0 months. e A “ + ” sign indicates a censored value. Study 3 Study 3 was a single-arm, multicenter, open-label trial of 26 patients with advanced SM. RYDAPT was administered orally at 100 mg twice daily with food. The median age in this group was 64 years, 58% of patients were male and most were Caucasian (81%). Eligibility criteria were similar to Study 2. By Valent criteria per investigator assessment, of 17 patients with SM-AHN, 10 achieved a response (1 partial, 9 major) by 2 cycles that was sustained for at least 8 weeks. Patients who received concomitant corticosteroids were included. Of the 6 patients with MCL, 1 achieved partial response and 1 achieved major response. Median duration of response (DOR) for either group had not been reached, with DOR ranging from 3.4+ to 79.2+ months in patients with SM-AHN and 28.6+ to 32.1+ months in patients with MCL. The subtype of SM in the remaining 3 patients was unconfirmed.

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: November 2021 PATIENT INFORMATION RYDAPT ® (rye-dapt) (midostaurin) capsules What is RYDAPT? RYDAPT is a prescription medicine used to treat adults: newly diagnosed with a certain type of acute myeloid leukemia (AML), in combination with certain chemotherapy medicines Your healthcare provider will perform a test to make sure RYDAPT is right for you. with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL) RYDAPT is not safe when given to children in combination with chemotherapy. It is not known if RYDAPT is effective in children. Do not take RYDAPT if you are allergic to midostaurin or any of the ingredients in RYDAPT. See the end of this leaflet for a complete list of ingredients in RYDAPT. Signs and symptoms of an allergic reaction to RYDAPT have included trouble breathing, flushing, chest pain, throat tightness, and swelling of your lips, mouth, or throat. Get medical help right away if you have any of these signs or symptoms. Before you take RYDAPT, tell your healthcare provider about all of your medical conditions, including if you: have any lung or breathing problems are pregnant or plan to become pregnant. RYDAPT may cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with RYDAPT or think you may be pregnant. Pregnancy Registry: There is a pregnancy registry that monitors the health of females and their babies exposed to RYDAPT during pregnancy. Females who have taken RYDAPT during pregnancy or have been exposed to RYDAPT during pregnancy through a male partner taking RYDAPT should contact Novartis Pharmaceuticals Corporation at 1-888-669-6682, or at https://report.novartis.com/ . If you are able to become pregnant, your healthcare provider may perform a pregnancy test within 7 days before you start RYDAPT. Females who are able to become pregnant should use effective birth control (contraception) during treatment with RYDAPT and for 4 months after the last dose of RYDAPT. Males who have female partners that are able to become pregnant should use effective birth control during treatment with RYDAPT and for 4 months after the last dose of RYDAPT. are breastfeeding or plan to breastfeed. It is not known if RYDAPT passes into your breast milk. You should not breastfeed during treatment with RYDAPT and for 4 months after the last dose of RYDAPT. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should I take RYDAPT? Take RYDAPT exactly as your healthcare provider tells you. Your healthcare provider will tell you how many capsules of RYDAPT you need to take. Do not change your dose unless your healthcare provider tells you to. Your healthcare provider will prescribe medicines to help prevent the nausea and vomiting during treatment with RYDAPT. Take RYDAPT 2 times a day (about every 12 hours apart). Take RYDAPT with food. Do not open or crush RYDAPT capsules. If you miss a dose of RYDAPT, take your next dose at your scheduled time. Do not take an extra dose to make up for a missed dose. If you vomit after taking a dose of RYDAPT, do not take an extra dose. Take your next dose at your scheduled time. What are the possible side effects of RYDAPT? RYDAPT may cause serious side effects, including: Lung problems. RYDAPT may cause lung problems that may lead to death when used alone or in combination with other chemotherapy medicines. Get medical help right away if you have any new or worsening lung symptoms, including cough, chest discomfort, or shortness of breath. The most common side effects of RYDAPT in people with AML include: low white blood cell counts with fever (febrile neutropenia) nausea redness, pain, or ulcers on the inside your mouth (mucositis) vomiting headache bruising muscle or bone pain nose bleeds device-related infection high blood sugar levels (hyperglycemia) upper respiratory tract infection abnormal electrocardiogram (QT prolongation) The most common side effects of RYDAPT in people with ASM, SM-AHN, or MCL include: nausea vomiting diarrhea swelling in your hands, feet, or ankles muscle or bone pain stomach-area pain tiredness upper respiratory tract infection constipation fever headache trouble breathing Call or inform your healthcare provider if nausea, vomiting or diarrhea occurs, gets worse or does not go away. RYDAPT may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility. Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking RYDAPT if you develop certain side effects during treatment with RYDAPT. Your healthcare provider will do blood tests to check you for side effects during treatment with RYDAPT. These are not all of the possible side effects of RYDAPT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store RYDAPT? Store RYDAPT at room temperature at 68°F to 77°F (20°C to 25°C). Keep RYDAPT in the original container to protect from moisture. Keep RYDAPT and all medicines out of the reach of children. General information about the safe and effective use of RYDAPT. Medicines are sometimes prescribed for conditions not listed in the Patient Information leaflet. Do not take RYDAPT for a condition for which it was not prescribed. Do not give RYDAPT to other people, even if they have the same condition or symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about RYDAPT that is written for healthcare professionals. What are the ingredients in RYDAPT? Active ingredient: midostaurin Inactive ingredients: carmine, corn oil mono-di-triglycerides, dehydrated alcohol, ferric oxide red, ferric oxide yellow, gelatin, glycerin 85%, hypromellose 2910, polyethylene glycol 400, polyoxyl 40 hydrogenated castor oil, propylene glycol, purified water, titanium dioxide, and vitamin E. Distributed by: Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 © Novartis For more information about RYDAPT, visit www.US.RYDAPT.com . T2021-150

Rydapt ® NDC 0078-0698-99 (midostaurin) Capsules 25 mg Rx only 56 soft capsules Contents: 2 packs containing 28 capsules each NOVARTIS PRINCIPAL DISPLAY PANEL Rydapt® NDC 0078-0698-99 (midostaurin) Capsules 25 mg Rx only 56 soft capsules Contents: 2 packs containing 28 capsules each NOVARTIS